SIGA Technologies (SIGA Technologies) Cash, Cash Equivalents, Marketable Securities : $150.1 Mil (As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is SIGA Technologies Cash, Cash Equivalents, Marketable Securities?

SIGA Technologies's quarterly cash, cash equivalents, marketable securities declined from Jun. 2023 ($76.21 Mil) to Sep. 2023 ($71.11 Mil) but then increased from Sep. 2023 ($71.11 Mil) to Dec. 2023 ($150.15 Mil).

SIGA Technologies's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($103.14 Mil) to Dec. 2022 ($98.79 Mil) but then increased from Dec. 2022 ($98.79 Mil) to Dec. 2023 ($150.15 Mil).

SIGA Technologies Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for SIGA Technologies's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SIGA Technologies Cash, Cash Equivalents, Marketable Securities Chart

SIGA Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

65.25

117.89

103.14

98.79

150.15

SIGA Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															98.79	115.68	76.21	71.11	150.15

SIGA Technologies Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

SIGA Technologies (NAS:SIGA) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

SIGA Technologies Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of SIGA Technologies's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

SIGA Technologies (SIGA Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SIGA Technologies Inc (NAS:SIGA) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

31 East 62nd Street, New York, NY, USA, 10065

Website

http://www.siga.com

SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus.

Executives

Evan A. Knisely	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Jay Varma	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Ford Harold Eugene Jr.	director	4921 WILLIAM ARNOLD ROAD, MEMPHIS TN 38117
James Antal	director	30952 STEEPLECHASE DRIVE, SAN JUAN CAPISTRANO CA 92675
Holly L. Phillips	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Gary J. Nabel	director	C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Julian Nemirovsky	director	35 EAST 62ND STREET, NEW YORK NY 10065
Edward P. Taibi	director	35 EAST 62ND STREET, NEW YORK NY 10065
Jaymie A Durnan	director	C/O SIGA TECHNOLOGIES, INC.,, 31 EAST 62ND STREET, NEW YORK NY 10065
Gomez Phillip Louis Iii	officer: Chief Executive Officer	7220 VAN NESS COURT, MCLEAN VA 22101
Daniel J Luckshire	officer: Executive VP & CFO	C/O SIGA TECHNOLOGIES, INC., 35 EAST 62ND STREET, NEW YORK NY 10065
Paul G Savas	director	35 EAST 62ND STREET, NEW YORK NY 10021
Julie Kane	director	77 BEALE ST, P.O. BOX 770000, SAN FRANCISCO CA 94177
Dennis E Hruby	officer: Chief Scientific Officer	SIGA TECHNOLOGIES, INC., 420 LEXINGTON AVENUE, SUITE 601, NEW YORK NY 10170
Michael J Bayer	director	1100 N GLEBE ROAD, ARLINGTON VA 22201